Epigenetic activation of EBV BGLF4 determines antiviral-based regimen response in EBV+CNS lymphoproliferative disease.

Weigel C, Klimaszewski HL, Tounkara F, Addissie S, Schlotter S, Pray B, Dugan JP, Haverkos BM, Villagomez L, Lustberg M, Porcu P, Voorhees T, Ambinder RF, Kenney SC, Fingeroth J, Delecluse HJ, Caligiuri MA, Alinari L, Bumgardner G, Oakes CC, Baiocchi RA

Open source

DOI: 10.1016/j.bneo.2026.100200
Published: 2026 May
Container: Blood neoplasia
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.bneo.2026.100200,
  title = {Epigenetic activation of EBV BGLF4 determines antiviral-based regimen response in EBV+CNS lymphoproliferative disease.},
  author = {Weigel C and Klimaszewski HL and Tounkara F and Addissie S and Schlotter S and Pray B and Dugan JP and Haverkos BM and Villagomez L and Lustberg M and Porcu P and Voorhees T and Ambinder RF and Kenney SC and Fingeroth J and Delecluse HJ and Caligiuri MA and Alinari L and Bumgardner G and Oakes CC and Baiocchi RA},
  year = {2026},
  journal = {Blood neoplasia},
  doi = {10.1016/j.bneo.2026.100200},
  url = {https://doi.org/10.1016/j.bneo.2026.100200}
}

RIS

TY  - JOUR
TI  - Epigenetic activation of EBV BGLF4 determines antiviral-based regimen response in EBV+CNS lymphoproliferative disease.
AU  - Weigel C
AU  - Klimaszewski HL
AU  - Tounkara F
AU  - Addissie S
AU  - Schlotter S
AU  - Pray B
AU  - Dugan JP
AU  - Haverkos BM
AU  - Villagomez L
AU  - Lustberg M
AU  - Porcu P
AU  - Voorhees T
AU  - Ambinder RF
AU  - Kenney SC
AU  - Fingeroth J
AU  - Delecluse HJ
AU  - Caligiuri MA
AU  - Alinari L
AU  - Bumgardner G
AU  - Oakes CC
AU  - Baiocchi RA
PY  - 2026
JO  - Blood neoplasia
DO  - 10.1016/j.bneo.2026.100200
UR  - https://doi.org/10.1016/j.bneo.2026.100200
ER  -

APA

C, W., HL, K., F, T., S, A., S, S., B, P., JP, D., BM, H., L, V., M, L., P, P., T, V., RF, A., SC, K., J, F., HJ, D., MA, C., L, A., G, B., CC, O., & RA, B. (2026). Epigenetic activation of EBV BGLF4 determines antiviral-based regimen response in EBV+CNS lymphoproliferative disease.. Blood neoplasia. https://doi.org/10.1016/j.bneo.2026.100200

Source records

pubmed · retrieved 2026-09-25T18:19:11.844Z
europe-pmc · retrieved 2026-09-25T18:19:11.831Z
doaj · retrieved 2026-09-25T18:19:11.843Z